Cortellini, Alessio http://orcid.org/0000-0002-1209-5735
Aguilar-Company, Juan
Salazar, Ramon
Bower, Mark
Sita-Lumsden, Ailsa
Plaja, Andrea
Lee, Alvin J. X.
Bertuzzi, Alexia
Tondini, Carlo
Diamantis, Nikolaos
Martinez-Vila, Clara
Prat, Aleix http://orcid.org/0000-0003-2377-540X
Apthorp, Eleanor
Gennari, Alessandra
Pinato, David J. http://orcid.org/0000-0002-3529-0103
Funding for this research was provided by:
DH | National Institute for Health Research (Imperial BRC)
Article History
Received: 4 May 2022
Revised: 3 August 2022
Accepted: 5 August 2022
First Online: 22 August 2022
Ethics approval and consent to participate
: OnCovid was granted central approval by the United Kingdom Health Research Authority (20/HRA/1608) and by the corresponding research ethics committees at each participating institution. Full waiver of consent due to the retrospective nature of the study was granted by the UK HRA in accordance with UK law.
: Informed consent was waived by competent authorities due to the anonymized nature of patient data and the retrospective design of the study.
: AC received consulting fees from MSD, BMS, AstraZeneca, Roche; speakers’ fee from AstraZeneca, MSD, Novartis and Eisai. AG has declared consulting/advisory role for Roche, MSD, Eli Lilly, Pierre Fabre, EISAI and Daichii Sankyo; speakers bureau for Eisai, Novartis, Eli Lilly, Roche, Teva, Gentili, Pfizer, AstraZeneca, Celgene and Daichii Sankyo; research funds: EISAI, Eli Lilly, and Roche. DJP received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, EISAI, Falk Foundation, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, DaVolterra and AstraZeneca; research funding (to institution) from MSD and BMS. The remaining authors declare no competing interests.